Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Disease & Drugs

Clinical Trials

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Clinical Trials

1,156 stories · every one Fact-Checked
Agenus botensilimab and balstilimab combination demonstrates pathological responses in the Phase 2 UNICORN colon cancer trial.Clinical TrialsAgenus Reports 36% Major Response With BOT+BAL in Colon CancerAgenus’ Phase 2 UNICORN trial demonstrated a 36% major pathological response rate and 29% pathological complete response rate with neoadjuvant botensilimab plus balstilimab in pMMR/MSS colon cancer.3 Nov 2026 · 4 min read
Fact-Checked
Teva Pharmaceuticals' investigational emrusolmin for multiple system atrophy following TOPAS-MSA Phase 2 trial discontinuation after interim futility analysis.Clinical TrialsTeva to Stop TOPAS-MSA Trial After Interim Futility FindingTeva Pharmaceuticals will discontinue its Phase 2 TOPAS-MSA trial evaluating emrusolmin in multiple system atrophy after an independent monitoring committee recommended stopping the study following a prespecified interim…2 Nov 2026 · 4 min read
Fact-Checked
CARDAMYST (etripamil) nasal spray and recurrent paroxysmal supraventricular tachycardia following catheter ablation.Clinical TrialsMilestone Reports 66.7% PSVT Conversion With CARDAMYST After AblationMilestone Pharmaceuticals reported Phase 3 RAPID subgroup findings showing that CARDAMYST (etripamil) nasal spray converted recurrent paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm within 30 minutes in four…2 Nov 2026 · 4 min read
Fact-Checked
Enlivex Allocetra investigational cell therapy for knee osteoarthritis showing intra-articular treatment and knee joint inflammation.Clinical TrialsEnlivex Reports 79.2% Allocetra Response in Older Knee OA PatientsEnlivex reported 12-month Phase IIa results for Allocetra in knee osteoarthritis, with 79.2% of patients aged 64 and older achieving a clinically meaningful response compared with 47.6% receiving…2 Nov 2026 · 4 min read
Fact-Checked
Sonoran Desert toad associated with naturally occurring 5-MeO-DMT and AtaiBeckley's investigational intranasal mebufotenin for treatment-resistant depression.Clinical TrialsLilly’s AtaiBeckley Reports Positive Mebufotenin Results in Depression TrialAtaiBeckley’s investigational intranasal mebufotenin, based on 5-MeO-DMT, a naturally occurring psychedelic found in Sonoran Desert toad secretions, demonstrated significant antidepressant effects in a 193-participant Phase 2b trial.2 Nov 2026 · 4 min read
Fact-Checked
InventisBio D-2570 selective TYK2 inhibitor Phase 2 clinical trial results in plaque psoriasisClinical TrialsInventisBio’s D-2570 Delivers Up to 90% PASI 75 Response in Psoriasis TrialInventisBio’s oral TYK2 inhibitor D-2570 demonstrated significant improvements in PASI 75, PASI 90 and PASI 100 responses in a Phase 2 trial involving patients with moderate-to-severe plaque psoriasis.…2 Nov 2026 · 4 min read
Fact-Checked
lingdolinurad-outperforms-febuxostat-gout-phase-2b-studyClinical TrialsAtom’s Lingdolinurad Delivers Strong Phase 2b Gout ResultsAtom Therapeutics’ lingdolinurad achieved higher serum urate target attainment than febuxostat in a Phase 2b gout study, with 91.9% of patients reaching the primary urate target at Week…2 Nov 2026 · 4 min read
Fact-Checked
Abbott's investigational SonicForce coronary intravascular lithotripsy system evaluated in the TECTONIC trial, reporting 97% procedural success in severely calcified coronary lesions.Clinical TrialsAbbott Reports Strong TECTONIC Results for SonicForce IVLAbbott’s pivotal TECTONIC trial met both primary endpoints, reporting 97% procedural success and a 0.3% 30-day target lesion failure rate with its investigational SonicForce coronary intravascular lithotripsy system.…2 Nov 2026 · 4 min read
Fact-Checked
Fexlamose inhaled therapy targeting pathological airway mucus in patients with COPDClinical TrialsAer Therapeutics Reports Phase 2a Failure for Fexlamose in COPDAer Therapeutics’ investigational therapy fexlamose failed to meet its Phase 2a efficacy endpoints in moderate-to-severe COPD, showing no improvement in pulmonary function or overall mucus-plug burden after 28…31 Oct 2026 · 4 min read
Fact-Checked
Libtayo cemiplimab adjuvant treatment showing sustained disease-free survival benefit in high-risk cutaneous squamous cell carcinomaClinical TrialsRegeneron’s Libtayo Maintains DFS Benefit in Longer-Term C-POST ResultsLonger-term Phase 3 C-POST findings showed sustained disease-free survival benefit with adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma.31 Oct 2026 · 4 min read
Fact-Checked
Pozdeutinurad URAT1 inhibitor demonstrates sustained serum urate reduction in Phase 3 REDUCE-2 gout study.Clinical TrialsSobi Reports Positive REDUCE-2 Results for PozdeutinuradSobi’s Phase 3 REDUCE-2 study found that pozdeutinurad 75 mg and 50 mg achieved significantly higher serum urate target rates than placebo at month 6, with reductions sustained…30 Oct 2026 · 4 min read
Fact-Checked
Acumen Pharmaceuticals' sabirnetug antibody fails to demonstrate clinical benefit despite amyloid plaque reduction in Phase 2 ALTITUDE-AD trial.Clinical TrialsAcumen Reports Sabirnetug Failure Despite Amyloid ReductionAcumen Pharmaceuticals reported that sabirnetug (ACU193) failed to demonstrate clinical benefit in the Phase 2 ALTITUDE-AD trial at either dose, despite significant amyloid plaque reduction.30 Oct 2026 · 4 min read
Fact-Checked
Page 5 of 97